(Q82452910)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20062089%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20062089%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

1

M A Gertz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20062089%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

R C Wolf

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20062089%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

I N M Micallef

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20062089%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

D A Gastineau

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20062089%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

11 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20062089%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20062089%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20062089%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20062089%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

1396-1403

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20062089%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/bmt.2009.370

16 January 2020

exact match

0 references

cites work

Managing relapsed and refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Current status of autologous hematopoietic stem cell transplantation in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Transplantation of hematopoietic stem cells from the peripheral blood.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

PBPC collection techniques: standard versus large volume leukapheresis (LVL) in donors and in patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Significance of low peripheral blood CD34+ cell numbers prior to leukapheresis: what should the threshold required for apheresis be?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Mobilization and harvesting of peripheral blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Factors associated with successful mobilization of progenitor hematopoietic stem cells among patients with lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Hematopoietic progenitor cell large volume leukapheresis (LVL) on the Fenwal Amicus blood separator

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Role of stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Remobilization of patients who fail to achieve minimal progenitor thresholds at the first attempt is clinically worthwhile

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Modelling cost-effectiveness of high-dose chemotherapy as treatment for relapsed aggressive non-Hodgkin lymphoma in an Australian setting

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Implementation of peripheral blood CD34 analyses to initiate leukapheresis: marked reduction in resource utilization.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Successful autologous bone marrow rescue in patients who failed peripheral blood stem cell mobilization

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Failure to achieve a threshold dose of CD34+ CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021

Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.370

7 January 2021